Showing 1233 results
-
Press Release /Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with…
-
Press Release /Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc. to add first-in-class disease modifying topical treatment for presbyopia patients…
-
Press Release /Novartis to broaden liver portfolio to deliver best-in-class single and combination therapies for non-alcoholic steatohepatitis (NASH) with advanced fibrosis and cirrhosis through an option,…
-
Press Release /Periodic Fever Syndromes are rare diseases mostly affecting children[1] and cause recurrent and disabling fevers with potentially life-threatening complications[2] Ilaris® (canakinumab) is…
-
Press Release /If approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)[1] Seizures are the most…
-
Press Release /Acquisition to add a once-daily oral H4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline Investigational…
-
Press Release /SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health Program uses smartphones and…
-
Press Release /
Novartis lance SMS for Life 2.0 au Nigeria pour aider à améliorer l'accès aux médicaments essentiels
SMS for Life 2.0 est lancé pour la première fois dans l'Etat de Kaduna, troisième région la plus peuplée du Nigeria, en collaboration avec le ministère de la Santé de l'Etat de Kaduna. Ce… -
Press Release /"SMS for Life 2.0" wird zum ersten Mal im Bundesstaat Kaduna, der bevölkerungsreichsten Region Nigerias, in Zusammenarbeit mit dem Gesundheitsministerium von Kaduna eingeführt. Das Programm nutzt…
-
Press Release /Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care…